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Background: TBX1 and CRKL haploinsufficiency is thought to cause the cardiac phenotype of the 22q11.2 deletion
syndrome. However, few unequivocal mutations of TBX1 and CRKL have been discovered in isolated conotrucal
heart defects (CTDs) patients. The aim of the study was to screen the mutation of TBX1 and CRKL in isolated CTDs
Chinese patients without 22q11.2 deletion and identify the pathomechanism of the missense mutations.
Methods: We enrolled 199 non-22q11.2 deletion patients with CTDs and 139 unrelated healthy controls. Gene
sequencing were performed for all of them. The functional data of mutations were obtained by in vitro transfection
and luciferase experiments and computer modelling.
Results: Screening of the TBX1 coding sequence identified a de novo missense mutation (c.385G→ A; p.E129K) and
a known polymorphism (c.928G→ A; p.G310S). In vitro experiments demonstrate that the TBX1E129K variant almost
lost transactivation activity. The TBX1G310S variant seems to affect the interaction of TBX1 with other factors. Computer
molecular dynamics simulations showed the de novo missense mutation is likely to affect TBX1-DNA interaction. No
mutation of CRKL gene was found.
Conclusions: These observations suggest that the TBX1 loss-of-function mutation may be involved in the pathogenesis
of isolated CTDs. This is the first human missense mutation showing that TBX1 is a candidate causing isolated CTDs in
Chinese patients without 22q11.2 deletion.
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Congenital heart defects (CHDs), consisting of heteroge-
neous anatomy with distinct phenotypic subtypes, are the
most common human birth defects worldwide, affecting
nearly 0.8% of live births. Of these cases, 15 ~ 20% are
CTDs [1]. CTDs are severe malformations associated with
cyanosis and many other serious manifestations of hypoxia
and are characterised by a disordered orchestration of
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unless otherwise stated.include tetralogy of Fallot (TOF), double outlet of right
ventricle (DORV), pulmonary atresia with ventricular
septal defect (PA/VSD), transposition of the great arter-
ies (TGA), interrupted aortic arch (IAA), and persistent
truncus arteriosus (PTA), leading to cardiac enlarge-
ment, ventricular dysfunction, poor quality of life, and
even sudden death in the absence of surgical treatment.
The pathogenesis of CTDs is heterogeneous and involves
multiple genes and environmental factors. Although our
understanding of molecular pathways in cardiac develop-
ment has grown remarkably in the past few years, the aeti-
ology of human CHDs cannot be identified or explained in
the majority of cases [2]. Caused by a heterozygous multi-
gene deletion, 22q11.2 deletion syndrome (22q11DS) is a
relatively common genetic disorder (1:4000 live births).
CTDs are a prominent part of the 22q11DS phenotype,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tients. Reports originating from Western countries associ-
ate 12.8-17.8% of CTDs to the del22q11, and our own work
showed a lower incidence (6.13%) in Chinese CTDs pa-
tients [3]. The TBX1 gene, a member of a phylogenetically
conserved T-box gene family of DNA-binding transcription
factors, is mapped to the 22q11.2, and is hypothesised to be
responsible for the cardiac phenotype of 22q11.2 deletion
syndrome. Mutations of the TBX1 gene have been detected
in some patients featuring DGS/VCFS who are otherwise
devoid of the 22q11.2 deletion [4]. Mutational analysis in
nonsyndromic CTDs patients only detected a insertion of
30 bp within exon 9c of TBX1, caused polyalanine stretches
[5,6]. To better address the issue of the link between TBX1
and isolated CTDs, we performed TBX1 gene sequencing
in a large sample of Chinese isolated CTDs patients without
22q11.2 deletion.
CRKL(CRK-Like), another gene located within the
22q11.2 and expressed in the developing heart, was
found to be deleted in a few CTDs patients with atyp-
ical distal 22q11.2 deletions not including TBX1 [7,8].
The Crkl-/- mice embryos had DORV, VSD [9,10]. Crkl
and Tbx1 genetically interact, and developmental de-
fects associated with loss of Crkl and Tbx1 were linked
to two major signalling pathways (RA and Fgf8) during
embryonic development in model organisms [10,11].
These lines of evidence led us to hypothesize that
mutations of CRKL may also be implicated in the patho-
genesis of human CTDs. To test this hypothesis, we
sequenced the exons and the flanking areas of CRKL
gene in all CTDs patients in our cohort.
Methods
Ethics statement
All the assessments were performed with the approval
of the Medical Ethics Committee of Shanghai Children’s
Medical Centre (SCMC) and the Medical Ethics Com-
mittee of Xinhua hospital. All written informed consent
was obtained from the parents of each patient and control.
Subjects
The patients were recruited prospectively in SCMC from
June 2008 to December 2009. The cardiac phenotype
was confirmed by angiocardiography and echocardiog-
raphy in all the patients. When available, the surgical
operative notes were reviewed. Of 212 CTDs patients,
199 (78 female, 121 male; median age 2.1 years) were
enrolled because they were negative for the 22q11.2
microdeletion when tested by MLPA using the SALSA
P250-A1 MLPA-DiGeorge syndrome test kit (MRC-
Holland, Amsterdam, The Netherlands) [3]. They in-
cluded 70 TOF, 50 DORV, 28 PA/VSD, 28 TGA, 4 IAA
and 2 PTA patients, as well as 17 other cases of conotrun-
cal malformations (11 single ventricle with malposition ofgreat arteries (SV/MGA), 4 hypoplastic right heart syn-
drome (HDHS), 2 coarctation of aorta (CoA)). The clinical
information of 199 patients was examined by trained clini-
cians and none of them had extracardiac anomalies and
features suggestive of 22q11.2 deletion syndrome. All of
the subjects were of Han ethnicity. Parental informed con-
sent was obtained for all of the patients enrolled before
blood samples were drawn at the time of catheterisation.
A total of 139 unrelated Han Chinese children (57 female,
83 male; median age 7.43 years; all physically and mentally
healthy) were included as normal controls. We detected
the cardiac morphology of these controls by transthoracic
echocardiography and confirmed they were normal. After
obtaining informed written parental consent, a peripheral
venous blood sample was obtained, and the genomic
DNA was extracted from peripheral lymphocytes using a
QIAamp DNA Blood Mini Kit according to the manufac-
turer’s instructions (Qiagen, Duesseldorf, Germany).
Sequencing
The coding regions of the three alternative spliced forms
of the TBX1A, TBX1B, TBX1C (Figure 1A) and CRKL
were sequenced in the 199 CTDs patients and 139 con-
trols. We designed primers that amplify all exons and
flanking intronic sequences. The primers (Table 1) were
designed following the corresponding genomic regions
available in the Genbank database (TBX1, NG_009229.10;
CRKL, NG_016354.1) using Primers3 software (http://
bioinfo.ut.ee/primer3/). The PCR was performed with the
genomic DNA and the products were sequencing on an
ABI 3130 sequencer (Applied Biosystems). The se-
quence traces were aligned with the reference sequence
using the GenBank BLAST program (http://blast.ncbi.
nlm.nih.gov/Blast.cgi).
Plasmid constructs
The TBX1 expression vector containing the cDNA of
human TBX1C was purchased from Origene (Rockville,
MD, USA). The TBX1 cDNA was digested and inserted
into the plasmid pcDNA3.1(+) at the KpnI and XhoI
sites. The mutant expression vectors were generated by
use of site-directed mutagenesis performed according to
the protocol provided by the Quickchange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, California, USA),
and the wild-type pcDNA3.1-TBX1 was used as the
template.
Four conserved T-half sites “ATTTCACACCT” were
oriented head to tail, similar to those reported by Sinha
et al.[12] and were synthesised and subcloned into the
KpnI −HindIII sites in the pGL4.25 [luc2CP/minP] plas-
mid (Promega, Madison, Wisconsin, USA) to generate
the 4XT/2-minP reporter construct (Figure 2A). The se-
quence and orientation of the luciferase reporter were
verified by DNA sequencing.
Figure 1 The screening results of the TBX1 coding sequence. (A) Schematic representation of the TBX1 gene. The conserved T-box domain is
marked with yellow squares and spans exons 3-7. The two variants described in this paper are indicated by black arrows. (B) Shown at the left
are the DNA sequences of the 385G→ A mutation (upper panel) and the wild-type TBX1 sequence (lower panel). The fragment was sequenced
from forward and reverse directions. Shown at the right is the homologues sequence alignment of a part of the T-box domain of TBX1 from vari-
ous vertebrates. (C) Shown on the left are the DNA sequences of the TBX1 gene with a 928G→ A change. The three electropherograms show
the homozygote AA, heterozygote GA, and homozygote GG. The homologues sequence alignment is shown at the right. The conserved amino
acids are shown with a grey background, and residue 129 and 310 is indicated with a black box.
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The transient transfection was performed with FuGENE
HD transfection reagent (Promega, Madison, Wisconsin,
USA) according to the manufacturer’s protocol for
adherent cells. The HEK293T and COS7 cells were
maintained in DMEM medium (Invitrogen, California,
USA) with 10% foetal calf serum (Invitrogen, Califor-
nia, USA) and were then co-transfected with 100 ng of
the wild-type or mutant TBX1 constructs, 500 ng of
the 4XT/2-minP reporter construct, and a renilla lucif-
erase pGL4.74 [hRluc/TK] vector (Promega, Madison,
Wisconsin, USA). The cells were harvested 40 h after
transfection. The firefly and renilla luciferase activity
were measured using the Dual Luciferase Kit (Pro-
mega, Madison, Wisconsin, USA) and the Centro XS3
LB 960 Microplate Luminometer (Berthold, Bad Wild-
bad, Germany) according to the manufacturer’s recom-
mended protocol. The activity of the firefly luciferase
was normalised to that of renilla luciferase. The results
shown are the mean ± s.e.m of three independent ex-
periments performed in triplicate.Molecular dynamics (MD) simulations of wild-type and
mutant TBX1
Based on the X-ray crystal structures (PDB entry: 4A04,
resolution 2.1 Å) [13], the models of TBX1 and its mu-
tant for the MD simulations were built in Sybyl version
6.8 (Tripos Inc., St. Louis, MO). First, the sidechains with
missing coordinates were reconstructed using the frag-
ment library of the Biopolymer module; then the modified
structures were subjected to energy minimization in the
Minimize module using the Powell method up to the
gradient tolerance of 0.05 kcal/(mol · Å) to relieve pos-
sible steric clashes and overlaps of side chains. The 3D
structural model of the mutant TBX1 was built up using
the xLeap module in the AMBER suite (version 8.0) [14].
MD simulations were conducted on the two systems
of wild-type and mutant TBX1 using the AMBER suite
of programs (version 8.0) with the parm99 force field
[15]. Each structure was prepared by using the xLeap
module in AMBER, in which protons were added to the
structure and all inoizable side-chains were maintained in
their standard protonation states at pH7.0. A truncated
Table 1 Primer sequences used to amplify and sequence all the coding exons of the TBX1 and CRKL gene and exon/
intron boundaries
Primers Orientation Sequences Fragment size
TBX1-EXON1 F 5’-AGGAGCAGATGTCTCAGCCC-3’ 594 bp
R 5’-CACCGGCTGCCTATACTCAC-3’
TBX1-EXON2 F 5’-ATGACGCCATAATCCTCTGG-3’ 725 bp
R 5’-TGTGTTTTCTCCCCTTTGCT-3’
TBX1-EXON3 F 5’-TCACGCAGCTCTCGCATTTC-3’ 628 bp
R 5’-CCGGCGGAGGATAGGTGTTA-3’
TBX1-EXON4 F 5’-CAAGCTCCCAGTTGAGTAGG-3’ 414 bp
R 5’-GCAGGTGCCTAAAGAGTTTC-3’
TBX1-EXON5 F 5’-GGCAGCAGAGGGTTCAATCT-3’ 457 bp
R 5’-GCCTCGCAGGGACTCTAAAG-3’
TBX1-EXON6 F 5’-TGACCCAGCCTCATCTTGGA-3’ 404 bp
R 5’-AGGTCTAAGCGGACCCACTG-3’
TBX1-EXON7-8 F 5’-GGTGCGCTTCTCCTAACACTC-3’ 722 bp
R 5’-GGAGAGGGCCGAGGAGTG-3’
TBX1-EXON9C F 5’-CCAAGAGCCTTCTCTCCGC-3’ 775 bp
R 5’-TGGGGAACCGGATACTTCGA-3’
TBX1-EXON9A F 5’-CGTTGGGAGATGCAGTCCT-3’ 853 bp
R 5’-GCTTACTGGACAGCAGCAC-3’
TBX1-EXON9B F 5’-CTGATGGTGTGTGAGGCTGA-3’ 636 bp
R 5’-CACCTCTTGCATGCACACTT-3’
TBX1-EXON10 F 5’-CTGCTCTGTTTGAGGTGGTT-3’ 632 bp
R 5’-ACGCATCAGCTTTTATGGGA-3’
CRKL-EXON1_1 F 5’- GACGGTGCTCCTGATTGGCT-3’ 747 bp
R 5’-CCCAGGGCAGGTGGAAGAAT-3’
CRKL-EXON1_2 F 5’-GGACAGCCGCCGCCCCTACC-3’ 434 bp
R 5’-CCCACCCCCCTATACAAGCA-3’
CRKL-EXON2 F 5’-CAGTGAGCTAAGATCACGCT-3’ 677 bp
R 5’-ATGTCAAAGGACCCAAAAAG-3’
CRKL-EXON3 F 5’-AAGGATCACTTGAGCCCAGG-3’ 376 bp
R 5’-AGGCAGAACAACAAAGCAGC-3’
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buffer around the complex and counterions were added
to maintain the electroneutrality of the two systems. To
avoid the instability that might occur during the MD
simulations, the solvated systems were subjected to
minimization for 5000 cycles with protein restrained
and followed by another 5000 cycles with the whole sys-
tems relaxed. Then, the systems were gradually heated
from 0 K to 300 K during the first 60 ps by three inter-
vals, followed by equilibrium for 80 ps under constant
volume and temperature condition. Afterwards, the
systems were switched to constant pressure and tem-
perature condition and equilibrated for 100 ps to adjust
the systems to a correct density. Finally, the productionsimulations were carried out in the absence of any re-
straint and two 5-ns MD simulations were then con-
ducted on the wild-type and mutant TBX1 to probe the
function of the mutation.
All the MD simulations were performed using the par-
allel version of PMEMD in the AMBER suite. The long-
range electrostatic interactions were calculated using the
particle mesh Ewald method, whereas the SHAKE algo-
rithm was employed to fix the lengths of the bonds in-
volving hydrogen atoms [16,17]. During the simulations,
the integration time step of 2 fs was adopted and struc-
tural snapshots were flushed every 500 steps (1 ps). The
non-bonded cut-off was set to 10.0 Å, and the non-
bonded pair list was updated every 25 steps. By applying
Figure 2 Transcriptional activation of luciferase reporter constructs by the wild-type and mutant TBX1. (A) Schematic diagram of
4XT/2-minP reporter construct. Four conserved T-half sites “ATTTCACACCT” were oriented head to tail, synthesised and subcloned into the
KpnI − HindIII sites in the pGL4.25 [luc2CP/minP] plasmid. (B) and (C) show that the 293 T or COS7 cells were co-transfected with the
4XT/2-minP reporter construct containing the T-box binding elements and either a pcDNA3.1 (+) control vector (Blank), the TBX1 wild-type
construct, or the mutant constructs. The results were normalized for transfection efficiency to a co-transfected renilla luciferase vector and
are shown as the mean ± SEM of three independent experiments performed in triplicate.
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was coupled to a 300 K thermal bath at 1.0 atm pres-
sure [18]. The temperature and pressure coupling con-
stants were set to 2.0 ps and 1.0 ps, respectively [14].
Results
Mutation screening of the TBX1 and CRKL gene in CTDs
patients without 22q11.2 deletion
Screening of the TBX1 coding sequence identified a
de novo variant, as well as one known polymorphism
G310S (Figure 1). The de novo mutation is localised in
exon 3 (c.385G→A; p.E129K) in heterozygosis (Figure 1B).
The patient was a 12 years old boy at the time of initial
admission to SCMC and suffered from PA/VSD and
patent ductus arteriosus (PDA). His height was 152 cm,
and weight 50 kg on admission. His appearance looked
normal. He didn’t show mental retardation. Due to
cardiac problem, he did not finish primary school.
Unfortunately he lost the opportunity to operation be-
cause of pulmonary hypertension and died at the age of
13. His parents are non-consanguineous marriage. The
mutation was not observed in both of his normal parents.
The E129K mutation, involving conversion from an acidic
amino acid residue (Glu) to an alkaline amino acid residue
(Lys), occurs within the evolutionarily conserved T-box
domain in the highly conserved residue found in TBX1
orthologues of human, chimpanzee, rat, mouse, cattle,
chicken, Xenopus, and Danio rerio (Figure 1B).
We also detected a homozygous single nucleotide
polymorphism c.928G→ A; p.G310S in one male pa-
tient with HDHS, TA, VSD, TGA, pulmonary stenosis(PS), and atrial septal defect (ASD). His parents, who were
verified to be carriers of heterozygosis, had no cardiac
phenotype. The heterozygous variant was detected in 15
CTDs patients and seven normal controls. The G310S is
located near the C-terminal of the T-box domain and
conserved in the TBX1 vertebrate orthologues of humans,
chimpanzees, rats, mice, Xenopus, and Danio rerios, but
not in cattle and chickens (Figure 1C).
We sequenced PCR products containing coding exons
from CRKL using the sanger method, and no mutations
were detected.
Functional analysis of the mutations
To examine further the functional significance of the de-
tected mutations in TBX1, we engineered the c.385G→A
(p.E129K) mutation in the human TBX1 cDNA. The non-
synonymous SNP c.928G→A (p.G310S) was constructed
simultaneously. The polymorphism G310S showed no sig-
nificant effect on the transcriptional activation in our
assay, in contrast to the wild-type TBX1. It exhibited a
slight decrease in transactivation relative to the wild-type
in the 293 T cell line, yet a slight increase in transactivation
in the COS7 cell line. The novel missense mutation E129K
showed significantly reduced transcriptional activity in the
293 T and COS7 cells lines in our assay compared with
the wild-type protein (p < 0.05) (Figure 2B and 2C).
Molecular models and MD simulations of wild-type and
mutant TBX1
To interpret the effect of the point mutation E129K on
the TBX1 function, we modelled the structure of the
Xu et al. BMC Medical Genetics 2014, 15:78 Page 6 of 9
http://www.biomedcentral.com/1471-2350/15/78TBX1 DNA binding domain on the basis of the TBX1
DNA crystal structure (PDB code 4A04) using Sybyl ver-
sion 6.8 (Tripos Inc. St. Louis. MO) and the structural
model of TBX1E129K using the xLeap module in the
AMBER suite (version 8.0). Residue glutamic acid 129
(E129) is an evolutionarily conserved residue within the
T-box domain (Figure 3). It is clear from the structure
that E129, which sits on a beta strand, interacts with
tryptophan 179 (W179), glutamine 277 (Q277) and ly-
sine 285 (K285) by forming hydrogen bonds (Figure 4C).
Q277 and K285 are located at the helix-turn-helix motif
on the C-terminal of the protein, which is involved in
recognising the DNA through its minor groove [15].
The terminal negative charges of the side-chain in the
E129 acidic residue are replaced with positive charges
(K129, alkaline) in the mutant E129K-TBX1 (Figure 4A
and B), leading to a complete disruption of the hydrogen
bonds between E129 and its surrounding residues
(Figure 4C and D) and a distortion of the binding
interface between the TBX1 and DNA (Figure 4B),Figure 3 The phylogenetic sequence alignment of the T-box domain
the N and C terminus of the T-box domain. The phylogenetic analysis is
residues that are identical to the TBX1 sequences are shaded. The red pent
in the TBX1 found in patients. The dotted line indicated the T-box domainwhich may have a negative effect on the protein-DNA
interaction and thus the associated transcriptional
activation/inhibition functions.
Discussion
The TBX1 gene is a member of the T-box gene family of
transcription factors that is characterised by a conserved
DNA binding domain throughout the metazoan evolu-
tion [19]. The members of the T-box gene family play a
crucial role in a wide variety of developmental processes
in vertebrate and invertebrate embryos [20]. The bio-
logical importance of these genes is emphasised by the
phenotypes of the patient carried loss-of-function muta-
tions of TBX3 and TBX5 [21-23].
TBX1 haploinsufficiency has long been known to be
crucial in the aetiology of 22q11DS. Mutation analysis
has revealed frameshift and missense mutations of TBX1
in patients with the 22q11DS-phenotype, but no detect-
able deletion [4,24,25]. Animal model experimental evi-
dence suggests that Tbx1 is required for normal heartand 20 additional amino acids from different species located at
from vertebrate mammals to marine zooplankton. The aminoacid
agram demonstrates the amino acid substitutions of E129K and G310S
.
Figure 4 Schematic diagram of TBX1 bound to DNA. (A) The wild type TBX1 structure with E129 is shown as sticks. (B) The superimposed
structures between the wild-type TBX1 (cyan) and the TBX1E129K (grey) and the carbon atoms from E129 and its mutant K129 are colored in green
and yellow, respectively, and the conformations are extracted from the end of the 5-ns simulations. (C) Local interactions with E129 in the wild-type
TBX1. (D) Local interactions with K129 in the mutant TBX1. The hydrogen bonds around E129/K129 are shown as dashed lines.
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of TBX1 has been discovered in isolated CTDs patients.
Tbx1 is expressed in the secondary heart field (SHF) and
positively regulates SHF cell proliferation and contribution
to the muscle layer of outflow tract (OFT), of which the
myocardium derives from the SHF [28-30]. We investi-
gated a cohort of isolated CTD patients without 22q11.2
deletion and identified one novel mutation (E129K) of
TBX1. E129K, located within the conserved T domain,
is predicted to affect TBX1-DNA interaction on the basis
of the structures of DNA-bound wild-type or mutant
TBX1 (Figure 3). This finding is in line with the experi-
mental data showing that in our transient transfection and
luciferase reporter assays, the TBX1E129K variant has
almost lost transactivation activity for the transcription
directed from the consensus palindromic DNA-binding
site (Figure 2B and C).
The T-box genes are exquisitely dose-sensitive and often
act in a combinatorial or hierarchical fashion [26,31]. The
T-box domain, as the basic characteristic of the T-box
family, is a DNA-binding region and a protein-protein
interaction domain for other transcription factors, chro-
matin remodelling complexes and histone-modifying
enzymes [31]. It has been suggested that Tbx1 interacts
with the BAF chromatin remodelling complex and his-
tone methylases to regulate transcription [32]. The
known variant, G310S, positioned in a conserved regiondownstream to the T-box domain, was found in our CTDs
patients and healthy controls. The TBX1G310S variant ex-
hibits opposite behaviour in the 293 T and COS7 cell
lines. In the 293 T cell line, the variant partially loses
the transactivation on reporter with the conserved half-
T sites (Figure 2B), whereas it slightly enhances the
transactivation in the COS7 cell line (Figure 2C). Prior
studies have reported that the TBX1G310S variant pre-
vents TBX1-SMAD1 interaction that could not affect by
the mutations that abolish transactivation [33]. We
hypothesise that there may be a critical region for
protein-protein interaction that resides downstream to
the T-box region, and the different behaviour of the
TBX1G310S mutant in the 293 T and COS7 cell lines
may be caused by the distinct cofactors for TBX1 func-
tion in those cells. Although the heterozygous variant
was found in the patients and controls, the homozygote
was only detected in a patient with complex CHD. We
cannot exclude that the TBX1G310S mutant protein
might have an effect on the pathogenesis of congenital
malformations.
CRKL gene lies within the typically 3 Mb deleted re-
gion in 22q11DS patients. CRKL encodes an SH2-SH3-
SH3 adaptor protein, and is part of a signalling pathway
that includes Focal adhesion kinase (FAK) and MAP
kinases (ERK1 and ERK2) [34]. The embryonic pheno-
types of murine neural crest conditional knockout of
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normalities [10,11,34]. These experimental observations
indicate that the Fak-Crkl-Erk signalling pathway is crit-
ical important for cardiac outflow tract development.
However, only four patients with CTDs have been re-
ported with atypical distal 22q11.2 deletion that involves
CRKL, but not TBX1 so far [8]. Sequencing analysis of the
alleles or the remaining allele failed to identify a CRKL
mutation [8,35]. In our study, CRKL was sequenced in 199
CTDs patients without extracardiac anomalies, and we
also failed to detect a mutation. We therefore speculate
that the coding region mutation of CRKL gene may not
implicated in the pathogenesis of CTDs.
We recognize some weaknesses that are inherent to
our study. We only sequenced the coding region and
flanking areas between exons and introns. In genome,
non-coding regions (promoter regions and regulatory
elements) play an important role on gene expression.
Further studies are needed to be carried out to clarify
the link between variants in non-coding regions and the
pathogenesis of CTDs.
Conclusions
We have demonstrated that a novel TBX1 nucleotide
sequence variant is a mutation that might be involved in
the pathogenesis of isolated CTDs in non-22q11.2 dele-
tion patients, based on the results of sequence align-
ment and functional analysis of the mutants. The novel
TBX1E129K mutant, hypothesised to have loss-of-function
status, may cause heart defects by haploinsufficiency.
Other than the E129K mutation, the known TBX1G310S
variant seems to affect the interaction of TBX1 with
other factors.
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